CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

CEO

Yehiel Tal

Employees

Country

Israel

ISIN

IL0004960188

Listings

0 Comments

Share your thoughts

FAQ

What is CollPlant Biotechnologies stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange CollPlant Biotechnologies stocks are traded under the ticker CPT.MU.

What were CollPlant Biotechnologies earnings last quarter?▼

CPT.MU earnings for the last quarter are -1.97 EUR per share, whereas the estimation was -2.04 EUR resulting in a +3.12% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does CollPlant Biotechnologies have?▼

As of September 08, 2026, the company has 39 employees.

In which sector is CollPlant Biotechnologies located?▼

CollPlant Biotechnologies operates in the Health & Wellness sector.

When did CollPlant Biotechnologies complete a stock split?▼

CollPlant Biotechnologies has not had any recent stock splits.

Where is CollPlant Biotechnologies headquartered?▼

CollPlant Biotechnologies is headquartered in Rehovot, Israel.